Aphria Signs Agreement to Provide Sponsorship and Medical Marijuana to Large Three-Year Observational Research Study - Seite 2

Added Neufeld, "Apollo is the foremost expert in Canada when it comes to cannabis-based research for chronic pain management. Using proprietary technology, Apollo can capture and analyze the cannabis strains and certain of the related underlying benefits specific to chronic pain. We have entered into this relationship with Apollo because they bring knowledge and expertise as well as integrity and commitment in line with Aphria's values and long-term goals."

To support its research efforts, Apollo is currently expanding its clinical research capacity, opening 5 research sites across Ontario, with plans to for an additional ten sites across Canada.

About Aphria

Aphria, a company continued under the laws of the Province of Ontario and based in Leamington, Ontario, is in the business of producing, supplying and selling medical marijuana pursuant to the Marihuana for Medical Purposes Regulations (the "MMPR"). Under the MMPR, Health Canada is responsible for the oversight of commercial medical marijuana growers such as Aphria. Aphria's common shares are listed on the TSX Venture Exchange under the ticker symbol "APH".

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS: Certain information in this news release constitutes forward-looking statements under applicable securities laws. Any statements that are contained in this news release that are not statements of historical fact may be deemed to be forward-looking statements. Forward-looking statements are often identified by terms such as "may", "should", "anticipate", "expect", "intend" and similar expressions. Forward-looking statements in this news release include, but are not limited to, statements with respect to Aphria's intended business focus, anticipated future demand for medical marijuana and Aphria's ability to meet that demand, Apollo's future expansion plans and expectations regarding participation in the study. Forward-looking statements necessarily involve known and unknown risks, including, without limitation, risks associated with general economic conditions; adverse industry events; marketing costs; loss of markets; future legislative and regulatory developments involving medical marijuana; inability to access sufficient capital from internal and external sources, and/or inability to access sufficient capital on favourable terms; the medical marijuana industry in Canada generally, income tax and regulatory matters; the ability of Aphria to implement its business strategies; competition; crop failure; currency and interest rate fluctuations and other risks.